| Adamas Pharmaceuticals focuses on therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Co.'s product, GOCOVRI (amantadine) extended-release capsules, is for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Co.'s partnered product, Namzaric® (memantine hydrochloride extended release and donepezil hydrochloride) capsules, are for the treatment of moderate to severe dementia of an Alzheimer's type, marketed in the U.S. by Allergan plc under a license agreement between Co. and Forest Laboratories Holdings Limited, a subsidiary of Allergan plc. We show 31 historical shares outstanding datapoints in our coverage of ADMS's shares outstanding history.|
Understanding the changing numbers of ADMS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMS by allowing them to research ADMS shares outstanding history
as well as any other stock in our coverage universe.